// App-Quantinova.ai

1620 : In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia

Researchers

Presenter

  • Jennifer Richmond

Principal Investigators

  • Kathryn Evans

  • Alissa Robbins

  • Raushan T. Kurmasheva

  • Peter J. Houghton

  • Malcolm A. Smith

  • Richard B. Lock

Medical Centers

  • Cancer Therapy Evaluation Program, Bethesda, MD

  • Children's Cancer Institute, Sydney, Australia

  • Centre for childhood cancer, Nationwide Childrens Hospital, Columbus, OH

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 47

  • Second mitochondria-derived activator of caspase

  • Tumor necrosis factor

Drug/Treatment

  • Vidaza

  • birinapant

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved